Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Upcoming Investor Conferences in November

SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
November 10, 2021 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2...
November 09, 2021 08:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting

Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data...
November 03, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
October 11, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate in Piper Sandler Investor Lung Day

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
October 06, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs

SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
October 01, 2021 08:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
September 20, 2021 16:07 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
September 16, 2021 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
September 16, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...